Summary

Global Dermal Toxicity Testing Market was valued at USD 2.10 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.15% through 2030. The Global Dermal Toxicity Testing Market is witnessing steady growth, driven by regulatory mandates, ethical concerns over animal testing, technological advancements, and increased investments in research and development (R&D). This market is essential to the pharmaceutical, cosmetic, chemical, and biotechnology industries, ensuring product safety and regulatory compliance before market entry.
Regulatory bodies such as the FDA (U.S.), EMA (Europe), and OECD have established stringent safety protocols for dermal toxicity assessment, compelling companies to adopt advanced testing methodologies. The industry is undergoing a significant transformation, fueled by regulatory changes, cutting-edge innovations, and growing consumer demand for safe, ethical, and cruelty-free products.
While challenges such as high initial costs and regulatory standardization remain, ongoing R&D efforts, expanding market opportunities in emerging economies, and strategic industry collaborations are unlocking new avenues for growth. With the increasing adoption of non-animal testing methods, the market is poised for continued expansion, reinforcing its critical role in shaping the future of safety testing across pharmaceuticals, cosmetics, and chemicals on a global scale.
Key Market Drivers
Growing Ban on Animal Testing and Shift Toward Alternative Methods
The increasing global restrictions on animal testing have become a significant catalyst for the growth of the Global Dermal Toxicity Testing Market. As ethical concerns, regulatory pressures, and technological advancements converge, industries are rapidly transitioning toward alternative testing methods that are more reliable, cost-effective, and aligned with modern scientific standards. Over the past two decades, several governments and regulatory bodies have implemented strict prohibitions on animal testing, particularly in the cosmetics, pharmaceuticals, and chemical industries. The Cosmetics Regulation (EC) No 1223/2009 introduced: A testing ban: Animal testing on finished cosmetic products has been banned since September 2004, and testing on ingredients has been banned since March 2009. These nations have followed suit with similar bans on animal-tested cosmetics. While the FDA does not outright ban animal testing, states like California, Illinois, and New Jersey have imposed restrictions, leading to increased adoption of alternative testing approaches. Historically a proponent of animal testing, China has relaxed its regulations, now allowing non-animal methods for certain imported and domestically manufactured cosmetics. As regulatory compliance becomes non-negotiable, companies worldwide are investing heavily in alternative toxicity testing solutions, thus fueling market growth.
Key Market Challenges
Validation of Alternative Methods
The validation of alternative methods can pose challenges and potentially hinder the growth of the global dermal toxicity testing market. While alternative methods are sought after due to their ethical considerations and scientific advancements, their validation process can be complex and time-consuming. The validation of alternative methods requires extensive research, data collection, and comparison to established reference methods, often including animal testing benchmarks. This process can be time-consuming and resource-intensive, slowing down the adoption of these methods. As a result, market growth might be hindered, especially in the short term. Regulatory bodies typically require validation data to demonstrate the reliability and predictability of alternative methods. The acceptance of these methods in regulatory frameworks may take time, as agencies need to be convinced of their equivalence to existing methods. This delay can slow down the market growth, as companies hesitate to fully adopt alternative methods until they receive regulatory approval. The validation process aims to establish consistent and reproducible results across different laboratories and testing conditions. Variability in results can arise due to differences in protocols, equipment, or expertise. This lack of consistency can lead to skepticism about the reliability of alternative methods, causing some companies to hesitate in adopting them until these issues are resolved.
Key Market Trends
Advanced In Vitro Models
Advanced in vitro models better replicate human skin physiology, allowing for more accurate predictions of dermal toxicity. These models can mimic skin barrier function, cellular interactions, and complex biological processes, providing more reliable insights into how substances interact with human skin. As accuracy improves, industries can confidently assess potential hazards and make informed decisions about product safety. The use of animals for testing raises ethical concerns, and industries are increasingly turning to non-animal methods. Advanced in vitro models offer an ethical alternative by eliminating the need for animal testing while still providing scientifically meaningful results. Brands that prioritize ethical testing practices can enhance their reputation and appeal to consumers who value cruelty-free products. Regulatory bodies are recognizing the value of advanced in vitro models for safety assessment. As these methods become more validated and established, regulatory acceptance is increasing. Industries can use these methods to fulfill regulatory requirements, which accelerates their adoption and drives market growth. In vitro models offer quicker results compared to animal testing, allowing industries to streamline their testing processes and reduce time-to-market. Additionally, the ability to test multiple substances simultaneously enhances efficiency. While initial setup costs might be involved, the long-term cost-effectiveness of in vitro models can drive their adoption and market growth. Advanced in vitro models can be customized to mimic specific skin types, conditions, and populations. This flexibility enables industries to tailor testing to their products' target audiences, improving the relevance and accuracy of toxicity assessments. This customization can attract industries seeking personalized and precise testing solutions.
Key Market Players
• SGS S.A.
• Covance, Inc
• Bio-Rad Laboratories Inc.
• Qiagen N.V.
• GE Healthcare
• Eurofins Scientific Inc
• Merck KgaA
• Thermo Fisher Scientific, Inc.
• Charles River Laboratories International, Inc.
• Catalent, Inc.
Report Scope:
In this report, the Global Dermal Toxicity Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Dermal Toxicity Testing Market, By Test Type:
o Skin Irritation Tests
o Skin Sensitization Tests
• Dermal Toxicity Testing Market, By Testing Method Type:
o In Vivo Testing (Animal-Based Tests)
o In Vitro Testing (Cell-Based or Tissue-Based Tests)
• Dermal Toxicity Testing Market, By End User:
o Pharmaceuticals industries
o Cosmetics and personal care products industry
o Chemical Industry
o Other
• Dermal Toxicity Testing Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Dermal Toxicity Testing Market.
Available Customizations:
Global Dermal Toxicity Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Dermal Toxicity Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Test Type (Skin Irritation Tests, Skin Sensitization Tests)
5.2.2. By Testing Method Type (In Vivo Testing (Animal-Based Tests), In Vitro Testing (Cell-Based or Tissue-Based Tests))
5.2.3. By End User (Pharmaceuticals industries, Cosmetics and personal care products industry, Chemical Industry, Other)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Dermal Toxicity Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Testing Method Type
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Dermal Toxicity Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Testing Method Type
6.3.1.2.3. By End User
6.3.2. Canada Dermal Toxicity Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By Testing Method Type
6.3.2.2.3. By End User
6.3.3. Mexico Dermal Toxicity Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By Testing Method Type
6.3.3.2.3. By End User
7. Europe Dermal Toxicity Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Testing Method Type
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Dermal Toxicity Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Testing Method Type
7.3.1.2.3. By End User
7.3.2. Germany Dermal Toxicity Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By Testing Method Type
7.3.2.2.3. By End User
7.3.3. United Kingdom Dermal Toxicity Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Test Type
7.3.3.2.2. By Testing Method Type
7.3.3.2.3. By End User
7.3.4. Italy Dermal Toxicity Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type
7.3.4.2.2. By Testing Method Type
7.3.4.2.3. By End User
7.3.5. Spain Dermal Toxicity Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type
7.3.5.2.2. By Testing Method Type
7.3.5.2.3. By End User
8. Asia-Pacific Dermal Toxicity Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Testing Method Type
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Dermal Toxicity Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Testing Method Type
8.3.1.2.3. By End User
8.3.2. India Dermal Toxicity Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Testing Method Type
8.3.2.2.3. By End User
8.3.3. Japan Dermal Toxicity Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Testing Method Type
8.3.3.2.3. By End User
8.3.4. South Korea Dermal Toxicity Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By Testing Method Type
8.3.4.2.3. By End User
8.3.5. Australia Dermal Toxicity Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By Testing Method Type
8.3.5.2.3. By End User
9. South America Dermal Toxicity Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Testing Method Type
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Dermal Toxicity Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Testing Method Type
9.3.1.2.3. By End User
9.3.2. Argentina Dermal Toxicity Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Testing Method Type
9.3.2.2.3. By End User
9.3.3. Colombia Dermal Toxicity Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Testing Method Type
9.3.3.2.3. By End User
10. Middle East and Africa Dermal Toxicity Testing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Test Type
10.2.2. By Testing Method Type
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Dermal Toxicity Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By Testing Method Type
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Dermal Toxicity Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type
10.3.2.2.2. By Testing Method Type
10.3.2.2.3. By End User
10.3.3. UAE Dermal Toxicity Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type
10.3.3.2.2. By Testing Method Type
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Dermal Toxicity Testing Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. SGS S.A.
15.1.1. Business Overview
15.1.2. Product & Service Offerings
15.1.3. Recent Developments
15.1.4. Financials (If Listed)
15.1.5. Key Personnel
15.1.6. SWOT Analysis
15.2. Covance, Inc
15.3. Bio-Rad Laboratories Inc.
15.4. Qiagen N.V.
15.5. GE Healthcare
15.6. Eurofins Scientific Inc
15.7. Merck KgaA
15.8. Thermo Fisher Scientific, Inc.
15.9. Charles River Laboratories International, Inc.
15.10. Catalent, Inc
16. Strategic Recommendations
17. About Us & Disclaimer